Influence of monocaprin on the permeability of a diacidic drug BTA-243 across Caco-2 cell monolayers and everted gut sacs.
This study explores the potential of the monoglyceride monocaprin as an enhancer of the epithelial permeability of the beta(3)-adrenoceptor agonist BTA-243, as an approach to improving the bioavailability of this drug. The permeabilities of BTA-243 and mannitol (paracellular marker) in Caco-2 cell monolayer and everted gut sac models in aqueous buffer (pH 6.8) in the presence of 1.3 and 2.0 mM monocaprin were compared with control (monocaprin-free) solutions over a period of 1 h. The transepithelial electrical resistance (TEER) of the Caco-2 cell monolayers was measured at regular time intervals throughout the experiment and after a recovery period of 30 h. Toxicological damage to the biological models associated with exposure to monocaprin was assessed by scanning electron microscopy and by the measurement of lactate dehydrogenase (LDH) release from everted gut sacs. The permeability of BTA-243 in epithelial monolayers was enhanced in the presence of 1.3 and 2.0 mM monocaprin. Measurements of TEER and mannitol permeability showed partial recovery of barrier properties after a 30 h period following exposure to 1.3 mM monocaprin. No structural damage was evident in these monolayers. Enhancement of Caco-2 permeability to BTA-243 by 2.0 mM monocaprin was significantly greater than by 1.3 mM but was irreversible; monolayers failed to recover their barrier properties after 30 h and changes in their gross morphology were observed. The mucosal to serosal transfer of BTA-243 in everted gut sac was enhanced but to a lesser extent than in the Caco-2 model. LDH release from everted gut sacs exposed to monocaprin was significantly less than that after exposure to Triton X-100, a nonionic surfactant known to cause membrane disruption.
Brown
J R
JR
School of Pharmacy and Pharmaceutical Sciences, University of Manchester, M13 9PL, Manchester, UK.
Collett
J H
JH
Attwood
D
D
Ley
R W
RW
Sims
E E
EE
D000818:Animals; D001682:Biological Availability; D018938:Caco-2 Cells; D002463:Cell Membrane Permeability; D002722:Chlorobenzenes / Q000493:pharmacokinetics*; D003998:Dicarboxylic Acids / Q000493:pharmacokinetics*; D017097:Electric Impedance; D005989:Glycerides / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007583:Jejunum / Q000378:metabolism*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008297:Male; D008353:Mannitol / Q000493:pharmacokinetics; D008855:Microscopy, Electron, Scanning; D017830:Octoxynol; D051381:Rats; D017207:Rats, Sprague-Dawley; D013501:Surface-Active Agents
C424888:BTA243; D002722:Chlorobenzenes; D003998:Dicarboxylic Acids; D005989:Glycerides; D013501:Surface-Active Agents; C004204:rac-glycerol 1-monodecanoate; D008353:Mannitol; D017830:Octoxynol; D007770:L-Lactate Dehydrogenase